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CatalysisRING ﬁnger domain and RING ﬁnger-like ubiquitin ligases (E3s), such as U-box proteins, constitute the vast
majority of known E3s. RING-type E3s function together with ubiquitin-conjugating enzymes (E2s) to medi-
ate ubiquitination and are implicated in numerous cellular processes. In part because of their importance in
human physiology and disease, these proteins and their cellular functions represent an intense area of study.
Here we review recent advances in RING-type E3 recognition of substrates, their cellular regulation, and their
varied architecture. Additionally, recent structural insights into RING-type E3 function, with a focus on im-
portant interactions with E2s and ubiquitin, are reviewed. This article is part of a Special Issue entitled:
Ubiquitin–Proteasome System. Guest Editors: Thomas Sommer and Dieter H. Wolf.
Published by Elsevier B.V.1. Introduction
Protein ubiquitination initiates with the ATP-dependent activation of
ubiquitin (Ub) by ubiquitin-activating enzyme (E1), where a thioester
linkage is formed between the C-terminus of ubiquitin and the active
site cysteine (Cys) of E1 (Fig. 1). Ubiquitin is then transthiolated to the
active site of one of ~40 different (in mammals) ubiquitin-conjugating
enzymes (E2), generating an E2~Ub thioester. Speciﬁcity of ubiquitin
modiﬁcation is achieved largely through ubiquitin protein ligases (E3),
which interact with both E2~Ub and the substrate to which ubiquitin is
to be transferred. Ubiquitination generally occurs on primary amines as
a consequence of nucleophilic attack on the E2~Ub linkage, resulting in
stable isopeptide (or peptide) linkages with the C-terminus of ubiquitin.
Ubiquitin can be transferred either to a lysine (Lys), or (less frequently)
to the N-terminus, of either a substrate or another ubiquitin molecule
to generate multi- or poly-ubiquitin chains. To a large extent, the nature
of these ubiquitin linkages speciﬁes the fate and function of themodiﬁed
protein (see Fig. 1 and legend for more detail).tin–Proteasome System. Guest
maa@mail.nih.gov
.V.E3s function by one of two generalmechanisms. They serve either as
catalytic intermediates in ubiquitination, akin to E1 and E2, or they me-
diate the transfer of ubiquitin directly from E2~Ub to substrate. The for-
mer mechanism is used by Homologous to E6-AP Carboxy Terminus
(HECT)-type E3s (reviewed in this issue by Martin et al). The latter
mechanism is a characteristic of Really Interesting New Gene
(RING)-type E3s. RINGs coordinate two Zn2+ ions in a cross-braced ar-
rangement (Fig. 2 and described in detail below) to create a platform for
binding of E2s. The RING-like U-box family of E3s adopts a similar struc-
ture to bind E2s but without employing Zn2+ coordination. Together,
RING (also known as RING ﬁnger, RING motif, or RING domain) and
RING-like E3s (plant homeodomain/leukemia-associated protein
(PHD/LAP) and U-box), collectively referred to as ‘RING-type’ in this re-
view, constitute the large majority of the over 600 E3s in mammalian
cells.
Any consideration of RING-type E3smust include their partners, the
E2s. E2s have a core conserved ubiquitin-conjugating (UBC) domain
that contains a conserved catalytic Cys (Fig. 2). Some E2s have inser-
tions within the UBC domain or N- or C-terminal extensions that confer
speciﬁc functions. For HECT E3s, ubiquitin chain linkage speciﬁcation
lies largely with the catalytic HECT domain, but the situation is more
complicated for RING-type E3s and their E2s. Some E2s are dedicated
to speciﬁc ubiquitin linkages; other E2s are intrinsicallymore promiscu-
ous with respect to the linkages they generate. Thus, a given RING-type
E3 can generate different ubiquitin linkages depending on the E2 with
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Fig. 1. Ubiquitination. Protein ubiquitination requires the sequential action of three classes of enzymes. First, ubiquitin (Ub) is activated in an ATP-dependent manner by
ubiquitin-activating enzyme (E1). In this step, the C-terminus of ubiquitin is linked by a thioester bond to the active site Cys of E1 (E1~Ub). Ubiquitin is then transthiolated to the active
site Cys of a ubiquitin-conjugating enzyme (E2), generating an E2~Ub thioester. Ubiquitin protein ligases (E3) interactwith both E2~Ub and the substrate towhich ubiquitin is to be trans-
ferred, thus providing much of the speciﬁcity in the ubiquitin system. HECT-type E3s function as covalent intermediates in the ubiquitination pathway as ubiquitin is ﬁrst transferred to
the active site Cys of E3 via a transthiolation before conjugation to substrate. RING-type E3s insteadmediate the transfer of ubiquitin directly fromE2~Ub to substrate. Ubiquitination gen-
erally occurs on primary amines (Lys, and, less frequently, a free N-terminus) as a consequence of nucleophillic attack on the E2~Ub linkage, resulting in stable isopeptide (or peptide)
linkages with the C-terminus of ubiquitin. Monoubiquitination plays diverse roles in processes such as DNA repair, protein trafﬁcking, and transcription [159], and recent ﬁndings
have demonstrated that multi-monoubiquitination can also target proteins for proteasomal degradation [160,161]. Alternatively, ubiquitin can be transferred to one of the seven Lys
(K) or the N-terminal Met of ubiquitin molecules [162] (PDB 1UBQ) that are already substrate-linked, generating multi- or poly-ubiquitin chains. To a large extent, the nature of the
ubiquitin linkages speciﬁes the fate and function of the modiﬁed protein. For example, chains of four or more ubiquitins linked through K48 efﬁciently target proteins for proteasomal
degradation [163]. Similarly, K11-linked chains are implicated in proteasomal targeting of anaphase-promoting complex/cyclosome (APC/C) substrates [164] and chains linked through
other lysinesmay also play a role in proteasomal targeting [165,166]. K63-linked and linear ubiquitin chains are integral to non-proteasomal aspects of NF-κB signaling [167]. K63-linked
chains and mono-ubiquitination are also implicated in DNA repair and the targeting of cell surface and endocytic proteins for lysosomal degradation [168,169].
48 M.B. Metzger et al. / Biochimica et Biophysica Acta 1843 (2014) 47–60which it is paired. Structural and functional properties of E2s have been
reviewed in detail elsewhere [1].
Mutation of RING-type E3s, or modulation of their activity in other
ways, is often associated with human disease. BRCA1, an E3 that plays
critical roles in DNA repair, is mutated in familial breast and ovarian
cancers [2]. Mutations in components of the FANC ubiquitin ligase,
also involved in DNA repair, result in themultisystemic Fanconi anemia
syndrome [3], which includes severe developmental defects and, in
children who survive, there is a marked increased risk of tumor devel-
opment. Mdm2 (or Hdm2 in humans) was ﬁrst characterized as a ge-
netic ampliﬁcation in mice associated with malignancy [4]. Indeed,increased activity of this E3 towards the tumor suppressor p53, either
through increased Mdm2 expression or loss of a negative modulator
of Mdm2 activity, is associated with human cancers, particularly those
50% that retain wild type p53 [5]. The F-box protein FBXO11, the sub-
strate recognition component of the multi-subunit SCFFBXO11 E3 (see
Section 3 below), functions as a tumor suppressor by targeting BCL6, a
transcription factor involved in B-cell differentiation and activation,
for degradation [6]. FBXO11 is mutated or deleted in diffuse large
B-cell lymphomas [6]. Mutations in VHL, the substrate recognition com-
ponent of the CRL2VHL E3, lead to themalignant vonHippel–Lindau syn-
drome, which presumably arises because of dysregulation of HIF1-α
AB
C
Fig. 2. RING domains coordinate Zn2+ in a crossbrace arrangement that serves as a plat-
form for E2 binding. A) Representation of the crystal structure of the TRAF6 RING domain
(blue) bound to the E2, Ubc13 (green) [89] (PDB3HCT) highlights a stereotypical RING:E2
interaction. The catalytic Cys of Ubc13 is highlighted in yellow, while its RING
domain-interacting regions are in purple. Yellow TRAF6 RING residues with sidechains
shown are those that coordinate Zn2+ (C3HC3D), forming the RING crossbrace structure
modeled in B). The two loops (Zn I, Zn II) and the intervening central α-helix formed by
this structure together serve as a conserved platform for E2 binding. B, C)Model of the in-
terleaved RING crossbrace structure (B) and consensus sequence (C). The eight
Zn2+-coordinating residues are shown in yellow and X is any amino acid.
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E3 Parkin are associated with autosomal recessive juvenile Parkinson-
ism (AR-JP) [7]. Additionally, a number of viruses, for example, herpes
simplex virus type 1 (HSV-1), encode RING-type E3s as virulence factors
[8,9]. In the case of HIV, the virus encodes an adaptor protein, Vpu, that
redirects SCFβTrCP to downregulate CD4 [10]. The importance of
RING-type E3s to human health and disease has contributed to their be-
coming an intensively-studied family of proteins. This review will pro-
vide an overview of their regulated function and structure and recent
advances in understanding how they mediate ubiquitination by E2s.
2. RING dimerization
RING-type domains are found in many different structural contexts.
Whilemany exist as single-chain enzymes (Fig. 3A), a notable feature of
RING-type E3s is their tendency to form homodimers and heterodimers
(Fig. 3C–F). Homodimeric RING-type E3s include cIAP, RNF4, BIRC7
(shown in Fig. 3D), IDOL, and the U-box proteins CHIP and Prp19
[11–17]. Examples of well-characterized heterodimeric E3s include
BRCA1–BARD1 (shown in Fig. 3F), Mdm2–MdmX (or HdmX/Hdm4 in
humans), and RING1B–Bmi1. While for homodimeric RING E3s both
RINGs have the intrinsic capacity to functionally interact with E2s, thisappears not to be the case for some heterodimeric RINGs. BRCA1 and
RING1B each functionwith E2,while their partners serve to enhance ac-
tivity, potentially interact with substrates, and, in the case of BRCA1–
BARD1, to stabilize the complex in vivo [18–21]. For the RING of
BARD1, its lack of E2 binding activity can be attributed, at least in part,
to the absence of a portion of the conserved central α-helix necessary
for E2 interactions [19,22]. In contrast, there is evidence that MdmX,
the ‘inactive’ partner, does physically interact with E2, in addition to
having the capacity to bind the best-characterized Mdm2–MdmX sub-
strate, p53. Importantly, while Mdm2 can homodimerize and is active,
MdmX has little tendency to form a homodimer and is inactive, and
the twoRINGs can form an active heterodimer [23,24]. This underscores
the important role played by RING dimerization (discussed further
below). Strikingly, MdmX's lack of in vitro activity can be restored by
mutating a single residue at the RING dimerization interface to that
found in the analogous position ofMdm2 [25]. However, additionalmu-
tations ofMdmX tomimic the nucleolar localization sequence ofMdm2,
found in its RING:E2 interface, are required for in vivo activity of MdmX
towards p53 [25]. Interestingly, since p53 exists largely as a homo-
tetramer [26], there is the potential to assemble four Mdm2–MdmX
heterodimers in close proximity. RING dimerization may also be a
mode of cellular regulation of ubiquitination, as occurs for cIAP1,
where its RING homodimerization interface is sequestered in a ‘closed’
inactive form until activation by IAP antagonists, such as SMAC (second
mitochondrial activator of caspases) or DIABLO (direct IAP-binding pro-
tein with low isoelectric point) [27]. Binding of SMAC or DIABLO to cIAP
stabilizes it in an ‘open’ conformation that allows RING dimerization
and thus, presumably, E2 binding and ubiquitin transfer.
RING-type dimers are generally formed in one of two ways: 1) se-
quences outside the RING are primarily responsible for dimerization;
or 2) the RING per se is responsible for dimerization. In both types, the
two RINGs are positioned such that the E2 binding surfaces face away
from each other (see Fig. 3D and F, surface highlighted in red), indicat-
ing that a direct cooperative interaction between the two RING-bound
E2s in the context of a dimer is unlikely. At present, there is more struc-
tural characterization of RING dimers of the second type (Fig. 3C andD),
which includes Mdm2–MdmX and homodimers of RNF4, IDOL, BIRC7,
and cIAP. These RINGs are all found at the extreme C-terminus of the
proteins containing them and the structures reveal that dimers are
formed via interleaved C-termini, explaining previous reports of the im-
portance of the C-termini in dimer stability and E3 ligase activity
[11–14,28]. In contrast, dimers of the ﬁrst type are formed via interac-
tions involving (usually) α-helical regions that ﬂank each of the two
RINGs (Fig. 3E and F). Proteins that formRINGdimers in thismanner in-
clude Rad18, BRCA1–BARD1, and RING1B–Bmi1 [19,29,30]; these di-
mers have their RINGs near their N- or C-termini. These two manners
of dimerization are not necessarily mutually exclusive and, in fact, the
available U-box structures of CHIP and Prp19 homodimers reveal dis-
tinct dimerization interfaces involving the U-box as well as regions N-
and/or C-terminal to the U-box domain [15,17]. Some RING-type E3s
have been shown to dimerize or form oligomers through domains
that are structurally distinct and remote from the RING. Interestingly,
proteins belonging to this group, such as Cbl family members and
gp78 [31–34], contain RINGs that are neither at the N- or C-terminus
of the E3. Higher-order oligomers that bring together multiple
RING-type dimers have also been reported for Prp19, which is active
as a tetramer [17].
3. Multi-subunit RINGs
There are RING-type E3s that exist as multi-subunit assemblies
(see Fig. 3B). A striking example is the Cullin RING Ligase (CRL) su-
perfamily [35], which exhibits enormous plasticity in substrate spec-
iﬁcity. Each CRL subfamily is characterized by a cullin protein (Cul-1,
2, 3, 4a, 4b, 5, or 7), a small RING protein (in most cases Rbx1/Roc1/
Hrt1), and either an adaptor protein(s) that binds interchangeable
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Fig. 3. Architecture of RING-type E3s. A) Model of a monomeric RING-type E3, where its RING domain would mediate binding to E2 thioester-linked to ubiquitin. Binding to substrate
occurs generally through regions of the E3 other than the RING domain. B) Model of a multi-subunit RING E3 of the cullin RING ligase (CRL) superfamily, such as the well-studied SCF
(CRL1) family, shown here. SCF consists of a cullin protein (Cul1) a small RING ﬁnger protein (Rbx1), and an adaptor protein (Skp1) that binds interchangeable substrate recognition el-
ements (F-box proteins). The ubiquitin-like molecule, Nedd8, is reversibly conjugated to cullins and associated with activation of CRLs. C) Schematic of dimeric RING E3s, such as cIAP,
RNF4, BIRC7, IDOL, Mdm2–MdmX, that dimerize through their RING domains and interleaved C-terminal tails. D) Ribbon diagram illustrating the homodimeric RING E3, BIRC7 [13]
(PDB 4AUQ) as a representative of the class of dimers schematized in C. The E2-interacting residues of one RING domain are highlighted in red. E) Model of dimeric RING E3s, such as
BRCA1–BARD1 and RING1B–Bmi1, where α-helices both N- and C-terminal to the RING facilitate dimerization. In the case of BRCA1–BARD1 (illustrated), this occurs through a four
α-helix bundle (helices above RINGs in F). F) Ribbon diagram illustrating the heterodimeric RING dimer of BRCA1–BARD1 [19] (PDB 1JM7) modeled in E). The E2-interacting residues
of the RING domain of BRCA1 are highlighted in red.
50 M.B. Metzger et al. / Biochimica et Biophysica Acta 1843 (2014) 47–60substrate recognition elements or, in the case of CRL3, proteins that
bind both to the cullin protein (Cul-3) and to substrate [36]. The
CRL superfamily is exempliﬁed by the well-studied Skp1-Cul1-F-box
protein (SCF) family (Fig. 3B), in which one of ~69 (in humans) inter-
changeable F-box proteins can potentially recognize substrates [37]
(reviewed in this issue by Bassermann et al.). Exchange of F-box pro-
teins within the SCF scaffold takes place through a complex cycle that
includes dynamic attachment and removal of the ubiquitin-like mod-
iﬁer, Nedd8 [38]. While the CRL superfamily overwhelmingly exhibits
the greatest range of substrate recognition, other multi-subunit E3s
exhibit even greater structural complexity. The anaphase promoting
complex/cyclosome (APC/C) is a highly complex E3 that in humans
contains 13 core subunits including a cullin-like protein and a smallRING protein. It also has two interchangeable co-activator subunits,
Cdc20 and Cdh1, which recognize distinct substrates and are active
during different phases of the cell cycle [39] (reviewed in this issue
by Bassermann et al.).
Another multi-subunit RING-containing ligase is the Fanconi anemia
(FANC) E3. There are at least 13 complementation groups associated
with this disease, and proteins corresponding to eight complementation
groups are components of the FANC ubiquitin ligase, including a
RING-type protein (FancL). This E3 is recruited to sites of DNA damage
to effect translesional repair. Despite its complexity, the role of the
FANC E3, as we currently understand it, is limited tomonoubiquitination
of two associated proteins that are subsequently deubiquitinated as part
of the DNA repair process. Degradation of a key FANC component,
51M.B. Metzger et al. / Biochimica et Biophysica Acta 1843 (2014) 47–60FANCM, via SCFβTrCP is responsible for inactivating the function of the
FANC E3 duringmitosis, thereby preventing chromosomal abnormalities
[3,5,40].
Some multi-subunit RING-type E3s contain multiple RING proteins.
The yeast GID (glucose-induced degradation deﬁcient) complex,
which targets fructose-1, 6 bisphosphatase for ubiquitination in re-
sponse to glucose, consists of seven subunits including two interacting
RINGs [41]. The yeast PEX ubiquitin ligase, which mono-ubiquitinates
the peroxisome receptor, Pex5p, and possibly other substrates, includes
three distinct RING proteins as part of a multi-subunit complex [42,43].
The speciﬁc function of each of the RINGs in such complexes is currently
unknown.
Finally, there are single proteins that contain multiple RINGs.
Mindbomb, involved in Notch signaling, has three RINGs in its C-
terminal region, although to date only the most C-terminal of these
has been studied and shown to be required for activity [44]. RING–
IBR–RING (RBR) proteins are a class of ~13 proteins (in humans) that in-
clude a RING consensus sequence (RING1) followed by a Cys-rich ‘in be-
tween RING’ (IBR) region and a third domain, the RING2, that was
originally characterized as a second RING-like domain. Although RBR
proteins were thought to function as canonical RING E3s, recent studies
have shown that they employ a RING–HECT hybrid mechanism
[45–49]. The RING1 domain binds E2 (similar to the RING mechanism)
but ubiquitin is transferred to a speciﬁc Cys within RING2 before being
transferred to substrates (similar to the HECT mechanism). Well-
known members of this family include Parkin, HHARI, HOIP, and
HOIL-1L. The latter two are subunits of the Linear Ubiquitin Chain As-
sembly Complex (LUBAC) E3 consisting of HOIP, HOIL-1L, and Sharpin
(a non-RING-containing protein). This complex plays critical roles in
NF-κB activation (reviewed in this issue by Kazuhiro et al).
4. RING-type E3s and their substrates
There is enormous diversity in substrate ubiquitination and its regu-
lation, as the targets of RING-type E3s are incredibly varied. RING-type
E3s are implicated as tumor suppressors, oncogenes, and mediators of
endocytosis, and play critical roles in complex multi-step processes
such as DNA repair and activation of NF-κB signaling. A RING-type E3
may have multiple substrates and several E3s can target the same sub-
strate. Not surprisingly, the mechanisms of substrate recognition by
RING-type E3s are highly varied, and occur in the context of networks
of interactions that often also include HECT E3s and deubiquitinating en-
zymes (DUBs). Substratesmay bind directly to a RING-type E3 ormay as-
sociate indirectly. The capacity of RING-type E3s for self-ubiquitination,
ﬁrst utilized as a means of assessing their potential to function with
E2s [50], frequently occurs in vivo, as does ubiquitination of RING E3s
by heterologous RING or HECT-type E3s as part of regulatory networks
[51].
E3-substrate interactions may be constitutive, and, in such cases,
regulation can occur at the level of E3 transcription or degradation.
The complexity of such trans-regulation is illustrated by the interplay
of SCF and APC/C E3s during the cell cycle where, for example, APC/
CCdh1 targets the F-boxprotein Skp2 for degradation in early G1, thereby
stabilizing p27 and preventing premature G1-S transition, and SCFβTrCP
targets the ‘pseudo-substrate’ and suppressor of APCCdc20, EMI1, for
degradation in late G2 [5] (reviewed in this issue by Bassermann et
al.). Similarly, SCFFBXO11 ubiquitinates and targets Cdt2, the conserved
substrate recognition subunit of CRL4Cdt2, for degradation, stabilizing
its substrates, such as p21 and Set8, and allowing for cells to properly
exit the cell cycle [52,53].
An emerging theme is a role for metabolites in substrate recogni-
tion and E3 activity. As above, the effect may be via a direct interac-
tion between a metabolite and a RING-type E3, or may be indirect,
for example via interaction with the substrate. In the latter category,
sterols serve as feedback regulators of their own synthesis by regulat-
ing the association of Insig-1 with the ER-resident RING E3 gp78 andhence the stability of the former, which is critical to the regulation of
cholesterol biosynthesis [54]. The plant hormones auxin and jasmonic
acid are examples of regulation by a direct metabolite:E3 interaction
[55,56]. These hormones bind directly to SCF complexes and target
transcriptional repressors for ubiquitination and degradation. This
strategy provides a way to de-repress gene expression and alter the
transcriptional proﬁle in response to environmental factors in plants.
Another intriguing example of regulation by a metabolite is a report
that the RING E3 TRAF-2 is inactive due to its RING structure being
unsuitable for E2 interactions, but is activated by its association
with sphingosine-1-phosphate [57]. A structural understanding of
how this occurs awaits further studies. Nevertheless, as nature rarely
uses a good idea just once, it seems likely that additional examples of
small molecule or metabolite activation (or inhibition) of E3s will be
uncovered in the future.
The most common means of regulating substrate ubiquitination is
by post-translational modiﬁcations that alter either ligase activity or
substrate recognition by RING-type E3s. Examples of regulation via pro-
tein phosphorylation are widespread. Regulated substrate phosphory-
lation on either Ser or Thr residues allows for the recognition of
numerous substrates by SCFβTrCP and SCFFbw7 [37]. Tyrosine phosphor-
ylation of activated receptor tyrosine kinases (RTKs) facilitates their
recognition by the Cbl family of RING E3s (Cbl, Cbl-b and Cbl-c) [58].
Cbl-c phosphorylation also modulates the dynamic interaction of its
RING with E2~Ub (see below). The net result of activation of Cbl family
members includes the ubiquitination of RTKs, leading to their lysosomal
degradation and an attenuation of signaling. Both phosphorylation of
the core RING subunit and dephosphorylation of Cdc20 play roles in
the activation of the APC/CCdc20 [59]. The level of complexity that phos-
phorylation offers is exempliﬁed by p53 and Mdm2. Regulated phos-
phorylation of speciﬁc residues on either p53 or Mdm2 can either
inhibit or enhance their interaction. Also,Mdm2degradation as a conse-
quence of self-ubiquitination is enhanced by phosphorylation, which
prevents interaction of Mdm2 with the DUB HAUSP/USP7. The failure
of Mdm2 to be deubiquitinated by USP7 leads to degradation of
Mdm2 and increased p53 activity under conditions of genotoxic stress
[5] (reviewed in this issue by Vousden et al).
A growing number of other post-translational modiﬁcations are
implicated in regulation of the ubiquitin system, including substrate
modiﬁcation by hydroxylation, glycosylation, acetylation, methyla-
tion, modiﬁcation by poly(ADP-ribose) (PAR), and attachment of
ubiquitin-like modiﬁers. The HIF1-α and HIF2-α transcription factors
undergo proline hydroxylation in response to increased oxygen levels
and become substrates for the multi-subunit RING E3, CRL2VHL. The
hydroxylation reaction is mediated by proline-hydroxylase domain
(PHD) proteins, which are themselves targets for SIAH RING E3s.
SIAH expression is positively regulated by HIF transcriptionally, creat-
ing a positive feedback loop to increase HIF1-α levels [5]. A subfamily
of F-box proteins, denoted as Fbs1–5, has the potential to recognize
glycosylated proteins in the cytosol, which have presumably been
transported out of the endoplasmic reticulum (ER). This provides a
means to target these displaced glycoproteins for ubiquitination and
proteasomal degradation [60].
Modiﬁcation of proteins with the small ubiquitin-like modiﬁer
(SUMO) family of proteins can inhibit substrate degradation by com-
peting for speciﬁc sites of ubiquitination or by altering the localization
of modiﬁed proteins. Perhaps a more general role for sumoylation is
to target proteins for ubiquitination, particularly those modiﬁed
with chains of SUMO (in metazoans SUMO 2/3). This occurs by
SUMO-targeted ubiquitin ligases (STUbLs), which contain multiple
SUMO-interactingmotifs (SIMs) in addition to their E3 ligase domains
[61].
The RING E3 RNF146 uses a WWE domain to recognize substrates
modiﬁed with poly(ADP-ribose) (PAR). In response to Wnt signaling,
axin is PARsylated by tankyrase and subsequently ubiquitinated by
RNF146, ultimately resulting in its proteasomal degradation. In vitro,
52 M.B. Metzger et al. / Biochimica et Biophysica Acta 1843 (2014) 47–60PAR as been shown to stimulate the ligase activity of RNF146, though
the mechanism is presently unknown [62–64]. There are other
RING-type E3s that contain WWE domains, including the Deltex fam-
ily, whose members play an important role in Notch signaling. Thus, it
is likely that additional examples of regulation by PARsylation will
emerge in the future.
There is a complex dynamic between ubiquitination, acetylation,
and methylation of lysines as part of the histone code [65]. Addition-
ally, there is data to suggest that speciﬁc lysines in p53 that are tar-
gets of Mdm2–MdmX are also acetylated, thereby preventing their
ubiquitination [66]. The acetylation of Mdm2 itself may decrease its
activity towards p53 [67]. There is also evidence for interplay be-
tween acetylation and ubiquitination of transcription factors such as
estrogen receptor-α [68].
Finally, for E3s to target substrates theymust exist in the same cellu-
lar compartment. Some RING-type E3s have nuclear localization signals
and many RING-type E3s are transmembrane proteins targeted to sites
such as the ER, plasmamembrane, endosomes, peroxisomes, and mito-
chondria [42,69–73].
5. RING-type domain structure
RING structure is conformed as a consequence of a cross-braced ar-
rangement of eight Zn2+ coordinating residues, generally Cys and His,
with conserved spacing between these residues (Fig. 2B and C). Canon-
ical RINGs have either one or two His in the linear arrangement of
coordinating residues, denoted C3H2C3 or C3HC4, however other varia-
tions exist. The PHD/LAP ﬁnger found in the transcription factor NF-X1
and theMARCH family of membrane-bound E3s is deﬁned by its C4HC3
consensus. RINGs having a C8 conﬁguration (CNOT4) or an Asp residue
in the ﬁnal position (e.g. Rbx1 and TRAF6) have been shown to have li-
gase activity [74–76]. Thus, it has become apparent that categorizing
RINGs by the linear arrangement of coordinating residues has little to
do with functional properties of the domain. Nevertheless, context
does matter, as swapping Zn2+ liganding residues in a C3H2C3 RING
to create a C3HC4 conﬁguration resulted in loss of activity for AO7
(RNF25), one of the ﬁrst RING E3s studied [50]. NF-X1 contains a se-
quence in which both a RING and a PHD/LAP motif are recognizable,
but only the PHD/LAP consensus is functional [77]. Unlike RING domain
E3s, U-box proteins do not coordinate Zn2+ but adopt a RING-like ter-
tiary structure for binding E2, stabilized by non-covalent interactions
among core amino acids [16]. Additionally, some pathogenic bacteria
have evolved proteins that show no sequence homology to eukaryotic
RING or U-box domains, yet fold into highly similar structures and dis-
play robust ubiquitin ligase activity [78,79].
Crystallographic and NMR-based analyses have revealed that RINGs
andU-boxes have a commonmodeof interactionwith E2s (Fig. 2A). The
key structural elements are two loop-like regions, which, in the case of
RINGs, coordinate Zn2+. The loops surround a shallow groove formed
by the central α-helix. Together these elements serve as a platform for
interactions with the UBC domain of E2s (Fig. 2A). The E2 surface that
interacts with the RING domain overlaps with the region that interacts
with E1, leading to the notion that dissociation of E2s from RINGs is re-
quired for an E2 to be ‘reloaded’with ubiquitin by E1 [80–82]. A charac-
teristic of RING:E2 interactions is that they are generally of low afﬁnity,
typically with Kd values in the high micromolar range. Thus, even
though a RING domain may function robustly with an E2, assessing
physical interactions between these proteins using standard ‘pulldown’
approaches is often not fruitful. Exceptions to this feature include E3s
such as gp78 [83], Rad18 [84], and AO7 [50] (S. Li, Y. Liang, X. Ji, &
A.M.W., unpublished observations), which contain regions outside the
RING motif that bind E2s through distinct interfaces, resulting in high
afﬁnity interactions (see below).
RING:E2 interactions typically involve conserved, bulky hydrophobic
side chains.Mutation of these side chainsmitigates E2 binding and causes
decreased levels of ubiquitination activity in vitro, as demonstrated forc-Cbl Trp408Ala [85], CNOT4 Leu16Ala [74], and BRCA1 Ile26Ala [86].
However, because a given RING can function with a cohort of E2s with
varying binding afﬁnities [86,87], mutation of such RING domain:E2 resi-
dues may yield unexpected results. For example, residual activity is ob-
served in vitro for the BRCA1 Ile26Ala mutant with select E2 pairings
(J.N.P., D.M. Wenzel, & R.E.K., unpublished observations), and the analo-
gous mutation in other RING E3s does not consistently eliminate activity
(J. Callis, UC Davis, personal communications). Thus, the relationship
between E2 binding and activity remains to be fully characterized and
will require mutants where, in the context of a correctly folded RING
(i.e. retaining its Zn2+-coordinating residues), E2 binding is abolished.
Conversely, in vivo analysis of RING function demands a truly ‘ligase-dead’
mutant that retains E2~Ub binding. Identiﬁcation of such mutants awaits
a more thorough deﬁnition of RING catalytic function.
6. RINGs as activators of E2~Ub
In contrast to HECT-type E3 ligases, RING-type E3s lack a bona ﬁde
catalytic center. A lingering question in the ﬁeld has been whether
RINGs serve solely to position E2~Ub relative to the substrate, or if they
also serve as activators of E2~Ub. Clearly, unwanted ubiquitination
events in the cell are detrimental, so it follows that the reactive E2~Ub
speciesmust be activated at the opportunemoment for transfer. Special-
ized examples have indeed provided evidence in support of an activating
role for RING E3s. One involves the E2 Ubc13 (Ube2N in humans), which
catalyzes free, K63-linked polyubiquitin chains in the presence of its ac-
cessory protein, Mms2. A crystal structure of the Mms2:Ubc13~Ub com-
plex revealed thatMms2 binds an incoming substrate ubiquitin in a way
that orients the ubiquitin K63 directly towards the Ubc13~Ub thioester
[88]. Thus, this heterodimeric E2 carries its own substrate-binding do-
main and does not require an E3 to coordinate substrate. Nevertheless,
ubiquitin chain formation by Mms2:Ubc13 is dramatically enhanced in
the presence of a minimal RING domain [89]. A second example, in-
spired by work of the late Cecile Pickart, showing E2-catalyzed Ub
transfer onto free Lys, demonstrates an increased rate of ubiquitin dis-
charge to small molecule nucleophiles in the presence of minimal
RING domains [45,90]. Use of these substrate-independent assays has
allowed theobservation of a catalytic role for RING-type E3s in ubiquitin
transfer reactions uncoupled fromproximity effects afforded by E3:sub-
strate interactions.
In all available E2:E3 structures, the RING-type domain binds the E2
on a surface that is remote from the active site Cys (and therefore from
the ubiquitin thioester) (Fig. 2). The non-contiguous E3-binding and ac-
tive sites on the E2 imply that the role played by a RING to facilitate
ubiquitin transfer may be indirect and, therefore, allosteric. However,
apo- and E3-bound E2 structures are largely indistinguishable and fail
to suggest amechanism for the allostery. Recent structural studies char-
acterizing the interactions of the more relevant E2~Ub conjugated spe-
cies with RING-type domains have provided much needed insight.
Notably, a solution-based study of E2~Ub conjugates established their
dynamic nature and that E2 and the thioester-linked ubiquitin adopt
an array of ‘open’ and ‘closed’ conformations [91] (Fig. 4A). Three struc-
tures of E2~Ub conjugates of the UbcH5 family (Ube2D1-3) in complex
with RING-type E3s (RNF4:UbcH5A~Ub, E4B:UbcH5C~Ub, and BIRC7:
UbcH5B~Ub) provide the ﬁrst glimpses at an E3:E2 complex poised to
transfer ubiquitin [13,92,93]. A striking common feature is a ‘closed’
conformation of the E2~Ub conjugate in which the Ile44 hydrophobic
surface of ubiquitin is positioned against the 310 helix, active site, and
helix 2 of E2 (Fig. 4A–C). In solution, where multiple species can exist
simultaneously, E3 binding promotes a population shift in the highly
ﬂexible E2~Ub towards closed conformations which, based on activity
data, primes the active site for transfer (Fig. 4A) [13,93,94]. The closed
E2~Ub states are readily disrupted and even conservative mutations of
hydrophobic residues in the interface between E2 and ubiquitin can de-
stabilize the closed state and greatly decrease E3-stimulated ubiquitin
transfer [93]. It is interesting to note that E2~Ub conjugates that
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Fig. 4. Activation of E2~Ub conjugates by RING-type domains. A) Schematic of ubiquitin
thioester linked to E2 sampling ‘open’ and ‘closed’ conﬁrmations in the absence of a RINGdo-
main (left). RING binding to E2~Ub promotes increased occupancy of closed conﬁrmations
needed for ubiquitin transfer (right). B) Ribbon diagram of BIRC7–BIRC7:UbcH5B~Ub (PDB
4AUQ) as an example of a RING-type E3:E2~Ub ternary complex. E3, E2, and ubiquitin are
blue, green, and red, respectively. The catalytic Cys of UbcH5B is labeled. Gray circles are
the zincs coordinated by the BIRC7 RINGs. C) The ribbon diagram shown in B, with the
ubiquitinmolecule removed and the residues on E2 or the RING domains that would contact
ubiquitin in red. The 310 helix, helix 2, and catalytic Cys of UbcH5B are labeled. D) A closer
viewof the E2 active site and ubiquitin C-terminus from the BIRC7–BIRC7:UbcH5B~Ub struc-
ture shown in B and C. The UbcH5B helix 2 (green) is positioned directly above Arg72. Res-
idues from BIRC7, UbcH5B, and ubiquitin are underlined in blue, green, and red
respectively. The hydrogen bonding network created by BIRC7 Arg286 (blue) and the E2
backbone of Gln92, the ubiquitin backbone of Arg72, and the side chain of ubiquitin Gln40
is shown. Residues colored in purple correspond to those that display NMR spectral effects
speciﬁcally arising from the E3:E2 hydrogen bond. The ‘up’ conformation of the Asp87 side
chain seen in this structure is shown in purple and red, the ‘down’ conformation, frequently
seen in structures in the absence of covalently-boundubiquitin is showncomingoff the back-
bonedirectly below in semi-transparent cyan andorange (taken fromPDB3UGB [170]). Con-
tacts made by the ‘up’ Asp87 conformation to Arg74 (red) of ubiquitin are shown. The side
chains of UbcH5B Gln92, Ub Arg72, and Ub Arg74 are not shown for clarity.
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an E3, such as Ubc13 [91], Ubc1 [95], Ube2S [96], and Cdc34 [97], also
demonstrate E3-independent ubiquitin transfer. In contrast, the
UbcH5 family of E2s, which shows robust activity with a large number
of RING-type E3s, has almost undetectable E3-independent activity,
consistent with its populating mainly open states in the absence of an
E3 [91].
Several non-mutually exclusive possibilities for how RING binding
promotes closed E2~Ub conformations are suggested by the recent
RING-type E3:E2~Ub structures. One possibility is through direct
RING–ubiquitin interactions. Available structures, however, show that
the extent to which the RING directly interacts with ubiquitin varies
among E3s (Fig. 4B and C). The interleaved homodimeric RING struc-
tures of BIRC7 and RNF4 show additional interactions required for
activity between the opposing (i.e. non-E2-binding) RING and the con-
jugated ubiquitin [13,92,98] (Fig. 4C, see the C-terminus of BIRC7
highlighted in red). As discussed above, E3s including Mdm2–MdmX,
XIAP, and IDOL also adopt an interleaved RING dimer structure and
therefore may adopt a similar strategy to enhance closed E2~Ub states.
However, monomeric RING-type E3s such as the U-box E3 E4B, or di-
meric E3s such as BRCA1–BARD1, which dimerize through regions out-
side of their RINGs, either lack the additional ubiquitin-interacting
surface used by the interleaved dimers or this surface is not available
to interact with ubiquitin. The presence or absence of additional RING
contacts with ubiquitin is consistent with reports that some E3s exhibit
a higher afﬁnity towards E2~Ub than the isolated E2, while others bind
them with afﬁnities that are indistinguishable.
A second non-conﬂicting possibility for howRING binding promotes
closed E2~Ub conformations is through allosteric activation in the con-
text of the E2~Ub. All three of the recent RING-type E3:E2~Ub structures
contain an Arg in loop 2 of the RING-type domain that is critical for
E3-enhanced activity (e.g. Fig. 4D, Arg286 of BIRC7, shown in blue).
Crystal structures of the dimeric RNF4 and BIRC7 complexes show the
side chain of this Arg hydrogen bonding with the backbone of the E2
(Gln92), the backbone of ubiquitin (Arg72), and the side chain of
ubiquitin residue Gln40 (Fig. 4D). While mutation of the analogous
Arg (Arg1143Ala) in the monomeric E4B only modestly decreases its
binding afﬁnity for E2, it leads to a substantial loss of closed E2~Ub con-
formations. Coincident with this is a disappearance of select NMR spec-
tral perturbations near the E2 310 helix associated with functional E2
binding and the formation of closed E2~Ub conformations. The
Arg-induced alterations near the E2 310 helix spanmuch of the distance
between the RING-binding surface and active site of E2, prompting
Pruneda et al. to propose that the interaction between this Arg and
the backbone of E2 is the allosteric ‘link’ underlying the observed
E2~Ub closed conformation and rearrangements near the active site
(Fig. 4D, magenta). Notably, a similar allosteric path had been proposed
previously for UbcH5 on the basis of a statistical coupling analysis of E2
primary sequences [99]. Interestingly, as noted above, the analogous
RING loop 2 Arg also contacts ubiquitin in the crystal structures of
RNF4 and BIRC7, and mutation of ubiquitin Gln40 (Gln40Ala or
Gln40Arg) affects E3-enhanced activity. However, the signiﬁcance of
the Arg interaction with Gln40 in promoting E2~Ub closed conﬁrma-
tions in the context of RING binding awaits further analysis. Notably,
only an Arg at this position can provide multiple hydrogen-bond do-
nors; even a Lys, the next the most prevalent amino acid found at this
position in RING-type domains, cannot do so.
Intriguingly, one E2 residue may serve as a molecular ‘gate’ to
allow the C-terminus of ubiquitin to access the closed E2~Ub confor-
mations favorable for ubiquitin transfer. This residue, Asp87 in UbcH5
family members, resides on one side of the opening that leads to the
active site Cys (Fig. 4D). In the structures of the RNF4 and BIRC7
RINGs bound to UbcH5~Ub, the Asp side chain is positioned to form
hydrogen bonds to the backbone of the ubiquitin C-terminal tail.
How RING binding promotes the positioning of this Asp is unclear,
but this may occur through the allosteric link between the critical
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observable changes in structure in this region when RING-type E3:E2
and RING-type E3:E2~Ub structures are compared, the effect is likely
to be a subtle one, probably involving small but important changes
in electrostatics. The steric and chemical nature of this molecular
gate is critical for activity, as even a Glu substitution severely impacts
ubiquitination [45]. The residue corresponding to Asp87 is conserved
as Asp, Asn, or Ser in most E2s, with the exceptions of UbcH7 and
UbcH8, neither of which has been shown to function with RING-type
E3s. Notably, the SUMO-speciﬁc E2, Ubc9, which encodes a Ser at the
position analogous to Asp87 in UbcH5C, makes a similar contact with
the C-terminus of SUMO in the SUMO–RanGAP1–Ubc9–Nup358 struc-
ture, consistent with a general mechanistic feature of ubiquitin and
ubiquitin-like transfer [100].
In sum, it is now clear that RING-type E3s are more than mere mo-
lecular scaffolds. By binding E2~Ub conjugates and promoting closed
conformations, RING-type E3s activate their cognate E2s to stimulate
ubiquitin transfer. Several non-mutually exclusive mechanisms for
how RING domains promote the structural arrangements associated
with increasedubiquitin transfer activity have been suggested by recent
studies, but all require further vetting with other RING-type domains
and E2s. Nevertheless, these studies suggest that it will be possible to
create ‘catalytic’ mutations within RING-type E3s that can be used in
place of, or together with, E2-binding mutations (such as the widely
used BRCA1–Ile26Ala) to create more profoundly ligase-dead versions
of RING-type E3s. Such strategies will pave the way for the generation
of new tools to be used in investigations of E3 cellular functions and
protein substrates.
7. E2-binding domains distinct from the RING domain
7.1. E2-binding domains found in RING proteins
In addition to canonical RING:E2 interactions, RING-type E3s can also
modulate E2 function using UBC-interacting domains separate from
their RINGs. Of the non-RING domains characterized structurally, most
contact the ‘backside’ of the E2 UBC, a region centered on its β-sheet, op-
posite its active site, and distinct from both RING- and E1-interacting re-
gions. The backside of some E2s interacts non-covalently with ubiquitin
via a hydrophobic patch formed by Leu8, Ile44, and Val70 within the
ubiquitin β-sheet [84,101,102] (Fig. 5A). This surface of ubiquitin is com-
monly recognized by ubiquitin-binding domains (UBDs) [103], and sim-
ilar to the interaction of ubiquitin with UBDs, the ubiquitin:E2 backside
interaction is of relatively low afﬁnity (Kd of ~300 μM) [102]. At least in
the case of BRCA1–BARD1, the ubiquitin:E2 backside interaction en-
hances processive polyubiquitination [102], potentially by facilitating in-
creased E2~Ub self-assembly. Several ubiquitin E2-variant (UEV)
proteins also bind ubiquitin via their backside site and the yeast ubiquitin
E2 Ubc4 interacts with the Ubl-protein, Nedd8, using the same interface
[104–106]. Arabidopsis thaliana membrane-anchored Ub-fold (MUB)
proteins bind to the backside of some E2s and target them to the plasma
membrane [107]. MUBs structurally resemble ubiquitin, but their
C-terminal CAAX motif, which speciﬁes lipidation [108], precludes po-
tential activation by E1. There are also several examples of backside bind-
ing to the SUMO E2, Ubc9 (see below).
The RING E3 Rad18 contains a C-terminal E2 backside-binding do-
main. Rad18 and its cognate E2, Rad6 (Rad6a/Ube2A and Rad6b/Ube2B
in mammals), are conserved and essential members of the DNA damage
response. Together, Rad18 and Rad6 speciﬁcally monoubiquitinate
proliferating cell nuclear antigen (PCNA), a modiﬁcation that recruits
translesion DNA polymerases to stalled replication forks [109]. Rad18 in-
teracts with Rad6 both canonically through its RING domain and via the
C-terminal domain, called the Rad6-binding domain (R6BD) [110–113]
(Fig. 5C). A crystal structure of the R6BD in complex with human
Rad6b revealed that the R6BD forms a ‘kinked α-helix’ that binds the
backside of the E2 [84]. The backside-binding site of the R6BD on Rad6signiﬁcantly overlaps with the low afﬁnity site of non-covalent
ubiquitin binding and, with a Kd of ~60 μM, the R6BD can effectively
compete with ubiquitin for binding to Rad6 [84]. R6BD binding does
not alter the rate of formation of the Rad6~Ub thioester. Instead,
the R6BD either in trans or in the context of intact Rad18 limits
the inherent ubiquitin chain-forming activity of Rad6 [84]. Such
modulation of activity likely serves to direct Rad6 towards
monoubiquitination, rather than polyubiquitination of PCNA, but
this hypothesis has been difﬁcult to assess directly as mutation of
the R6BD also reduces PCNA monoubiquitination.
Bre1 and Ubr1, two other RING E3s that can partner with Rad6 in
yeast, also contain secondary binding sites for Rad6 [114–116]. The
human RAD6/BRE1 pair monoubiquitinates histone H2B inmammalian
cells [115], raising the interesting possibility that Bre1 also restricts the
activity of Rad6 to monoubiquitination through its secondary E2 bind-
ing site. The non-canonical Rad6-binding region of Ubr1, called the
basic residues-rich (BRR) domain, mediates a low afﬁnity (millimolar
level) interaction with the backside of Rad6 [84,116]. Unlike the R6BD,
though, the BRR domain does not outcompete ubiquitin for binding to
the backside of Rad6 [84]. The Ubr1/Rad6 pair polyubiquitinates N-end
rule substrates [116–118], making it unlikely that binding through the
BRR domain negatively regulates Rad6 function in a manner similar to
the R6BD.
Another E2 backside-binding domain is found in the human
pro-metastatic [119] RING E3 gp78, which functions in ER-associated
degradation (ERAD) with the E2 Ube2g2 (originally known as
MmUbc7 [120]). The Ube2g2-binding region (G2BR) of gp78 is a discrete
C-terminal domain that is necessary and sufﬁcient for interaction with
Ube2g2 [121]. The G2BR forms a high-afﬁnity (Kd of ~20 nM) complex
with the backside of Ube2g2 that would preclude ubiquitin from binding
to this same surface [83]. In contrast to the R6BD,G2BR binding toUbe2g2
stimulates polyubiquitin chain formation, evenwhen added in trans to re-
actions containing gp78 lacking the G2BR. Intriguingly, polyubiquitin
chain formation by two other Ube2g2-interacting RING E3s, hsHRD1
and Trc8, can also be stimulated by the G2BR when provided in trans.
Crystal structures of the G2BR bound to Ube2g2 reveal it to be a
single α-helix (Fig. 5D). Relative to their respective E2s, the G2BR is
oriented approximately perpendicular to the R6BD [32,83,84]. The ef-
fect of G2BR binding on ubiquitination by Ube2g2 is mediated by two
distinct allosteric mechanisms [83]. First, G2BR binding ‘locks’ loops
surrounding Ube2g2's catalytic cysteine into more ‘closed’ orienta-
tions and reorients the catalytic cysteine away from the accessible ac-
tive site region deﬁned by the orientation of the loops. These changes
are associated with a decreased rate of E1-dependent ubiquitin load-
ing of Ube2g2. Second, the G2BR increases the afﬁnity of Ube2g2 for
the gp78 RING domain almost 50-fold. The latter effect is most signif-
icant in the overall stimulation of ubiquitin transfer, as the increased
afﬁnity of Ube2g2 for the gp78 RING domain accounts for the ob-
served stimulation of ubiquitination.
The high afﬁnity interaction of gp78 with Ube2g2 afforded by bind-
ing of two discrete domains raises the question of how Ube2g2 can be
reloaded with ubiquitin by E1, whose binding site on E2 overlaps with
the site of RING binding [80–82]. Reloading of an E2 with ubiquitin by
E1 (or at least, dissociation of a discharged E2 to allow association of a
charged E2~Ub) must occur to achieve substrate polyubiquitination, al-
though the G2BR-dependent transfer of active-site cysteine-linked
ubiquitin chains from Ube2g2 to substrate has been reported [32,122].
In this system, a full description of the dynamics of the G2BR and RING
domain interactions with E2, in the context of the putative oligomeriza-
tion of gp78 through a distinct region [32],will be needed to provide fur-
ther insight into mechanisms of ubiquitination. Interestingly, the
non-RING-containing protein, ancient ubiquitous protein 1 (AUP1),
also contains a G2BR-like region that binds and recruits Ube2g2 to
lipid droplets [123,124]. Whether the AUP1 G2BR-like region has an ef-
fect on ubiquitination by Ube2g2 is not yet known and a precise role for
Ube2g2 in lipid droplets has not yet been described.
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Fig. 5. E2 binding domains other than the RINGmodulate ubiquitination by binding to the ‘backside’ of E2s. A–F) Structures of A) ubiquitin (red, PDB 2FUH [102]); B) SUMO (orange, PDB
2UYZ [151]); or the non-RING E2 binding domains (blue) found in C) Rad18 (R6BD, PDB 2YBF [84]); D) gp78 (G2BR, PDB 3H8K [83]); E) Cue1p (U7BR, PDB 4JQU [141]); or F) Pex22p
(Pex22pS, PDB 2Y9M [148]) binding to the ‘backside’ of their respective E2s (labeled and shown in green). The catalytic cysteine of each E2 is highlighted in yellow. The
thioester-linked ubiquitin interaction surface is colored in magenta in panel A.
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ity for the Cbl E2, UbcH5B. As mentioned above, Cbl proteins down-
regulate signaling pathways by mediating ubiquitination, endocytosis,
and ultimately lysosomal degradation of RTKs such as epidermal growth
factor receptor (EGFR) [85,125–127]. The three Cbl proteins have a con-
served N-terminal tyrosine kinase-binding (TKB) domain, connected by
a short linker to their RING domain [128]. The N-termini of Cbl proteins
inhibit their RING-dependent autoubiquitination, and Cbl activation re-
quires phosphorylation of a conserved tyrosine in the linker region im-
mediately N-terminal to the RING [129,130]. Intriguingly, recent
structural studies with Cbl and Cbl-b revealed that linker tyrosine phos-
phorylation and substrate binding combine to stimulate release of the E2
binding face of the RING from auto-inhibition by the TKB region
[131,132]. Together, phosphorylation and substrate binding to the E3
serve to enhance binding of both Cbl and Cbl-b to E2. On the other
hand, for Cbl-c, tyrosine phosphorylation decreases the afﬁnity of the
E3 for E2 by >3-fold (to a Kd of ~1 μM) [129]. The decrease in afﬁnity
may allowmore rapid cycling of E2 on and off of Cbl-c, thereby potential-
ly explaining the inhibition of autoubiquitination by the N-terminus for
this E3. However, how these two disparate ﬁndings ﬁt together will re-
quire further investigation.7.2. Enhancement of RING E3 activity by non-RING accessory proteins
E2-binding domains that enhance RING-dependent ubiquitination
have been identiﬁed in several non-RING-containing accessory pro-
teins. A paradigm example is Cue1p, a transmembrane protein that re-
cruits the yeast ERAD E2, Ubc7p, to the ER-localized HRD1 (Der3p) and
DOA10 RING E3 complexes [133–135]. Cue1p is also required for the
stability of Ubc7p [136–138]. Cue1p's function expands beyond these
roles, as a stable, membrane-anchored form of Ubc7p still requires
Cue1p for ERAD [139,140]. Ubc7p is the yeast ortholog of mammalian
Ube2g2, and like the G2BR, Cue1p stimulates RING-dependent
ubiquitination with Ubc7p [139,140]. E2 binding by Cue1p occurs
through a C-terminal domain called the Ubc7p binding region (U7BR)
[136,140], which shows onlymodest overall (~15%) sequence similarity
to the signiﬁcantly shorter G2BR. The U7BR folds into a multi-helical
structure whose central helix is ~40% identical to the G2BR and orients
on the backside of Ubc7p similarly to the G2BR on Ube2g2 (Fig. 5E
[141]). Also, like the G2BR, the U7BR increases the afﬁnity of Ubc7p
for RING domains [141]. However, U7BR binding also imparts several
distinct allosteric effects on Ubc7p. The E2's catalytic Cys is more acces-
siblewhenUbc7p is bound to the U7BR, an effect that correlateswith an
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crease in the rate of RING-independent ubiquitin transfer when U7BR is
bound. Uniquely, Cue1p's ability to enhance ubiquitin loading indicates
that Ubc7p could remain associated with the HRD1 or DOA10 E3 com-
plexes via Cue1p while being reloaded with ubiquitin by E1, something
that RING binding precludes. In support of this, modeling of E1 onto
the Ubc7p:U7BR structure based on the recent crystal structure of
Schizosaccharomyces pombe ubiquitin E1 (Uba1) in complex with S.
pombe Ubc4 [142] (PDB 4II2) indicates that E1 and U7BR could be mu-
tually bound to Ubc7p. Interestingly, similar analysis predicts that si-
multaneous binding of E1 and G2BR to Ube2G2 would be precluded;
however, this is not the case for the R6BD or Pex22pS (see below). It is
interesting to consider how the U7BR, being part of a protein distinct
from the RING itself, affords ﬂexibility to the system and could allow
Ubc7p to simultaneously bind to E1 or pair with various RING E3s in
vivo.
Another example of activation of an E2 by a non-RING E3 protein is
the yeast E2 Pex4p, which is recruited to the peroxisome by the trans-
membrane protein, Pex22p [143–145]. Pex4p functionswith a complex
of RING E3s (Pex2p, Pex10p, Pex12p) [146] to monoubiquitinate Pex5p
on a speciﬁc Cys residue, required for efﬁcient peroxisomal protein im-
port [147]. Pex22p binds to Pex4p with high afﬁnity (Kd of ~2 nM) and
its binding stimulates the formation of lysine-linked ubiquitin chains on
Pex4p in the absence of a RING domain. Pex22p:Pex4p binding is also
required for RING-dependent substrate ubiquitination in vivo [148].
The enhancement of ubiquitin transfer activity does not appear to be
mediated by an enhancement in the rate of E1 loading of Pex4p [148].
A crystal structure of the soluble portion of Pex22p (Pex22pS) with
Pex4p reveals that Pex22pS adopts a novel mixed β-sheet and α-helix
fold that contacts the C-terminal α3 and α4 helices of the E2, adjacent
to the backside region [148] (Fig. 5F). The molecular mechanism of
Pex4p stimulation by Pex22p remains unknown, and the binding to
this distinct region of the E2 by Pex22pmay reﬂect a novel mode of reg-
ulation as well. Further investigation will reveal whether Pex22p and
AUP1 (described above) have similar or distinct mechanistic effects on
their respective E2s as the other E2 binding domains whose functions
have now been described.7.3. Parallels in the SUMO system
FewE3 ligases have been identiﬁed and characterized for SUMOand,
to date, no HECT-type SUMO E3s have been identiﬁed. Although the
known SUMO E3 ligases are not structurally similar to RINGs, like
RING-type E3s, they facilitate direct transfer of SUMO from the sole
SUMO E2, Ubc9, to a substrate Lys. Thus, it is informative to compare
and contrast features and strategies used by the SUMO system to
those of the ubiquitin system. Ubc9 interacts non-covalently with
SUMO via the analogous E2 backside site and SUMO β-sheet
[149–151] (Fig. 5B). Like ubiquitin binding, non-covalent SUMObinding
to Ubc9 promotes SUMO chain formation on target proteins [149,151].
Furthermore, the SUMO E3 Nup358/Ran-binding protein 2 (RanBP2),
which is involved in nucleocytoplasmic trafﬁcking [152–154], despite
being structurally distinct from SUMO, contacts the Ubc9 backside
using the same residues on Ubc9, making their bindingmutually exclu-
sive [149]. How SUMO andNup358/RanBP2 interact in vivo tomodulate
function remains to be determined.
SUMO accessory proteins also contain domains that, despite very
little sequence identity, structurally mimic SUMO and bind the back-
side of Ubc9. An example is Rad60/Esc2 and its human ortholog, nu-
clear factor of activated T-cells (NFAT)-interacting protein of 45 kDa
(Nip45), which contains a C-terminal SUMO-like domain (SLD) that
is a structural mimic for SUMO with respect to the Ubc9-interacting
region [155,156]. Notably, binding of SLD2 to the backside of Ubc9 in-
hibits SUMO chain elongation in vitro and is important for survival of
genotoxic stress in yeast [155,156].Another putative SUMO accessory protein, the RWD domain-
containing protein RSUME, enhances SUMO conjugation in several
ways including: stimulating the loading of Ubc9 with SUMO, mediating
E3-independent SUMO transfer to substrates, such as IκB and HIF-1α,
and stimulating sumoylation by the SUMO E3, PIAS [157]. RSUME
binds to both SUMO and Ubc9 and enhances the non-covalent SUMO
binding to Ubc9 [157]. Interestingly, like other RWD domains [158],
the structure of RSUME closely resembles that of E2 Ub-conjugating en-
zymes, despite limited sequence homology (PDB 2EBK).
8. Perspective and future directions
In the 14 years since RING ﬁnger function was discovered, our
knowledge of RING-type ubiquitin ligases has increased dramatically.
Through their targeting of a diverse array of substrates, we are begin-
ning to appreciate the range of roles played by this family of E3s in
development, in maintaining homeostasis, and in response to cellular
signals. Many challenges remain, however, as exempliﬁed by the fact
that substrates for most RING-type E3:E2 pairs are not yet known,
For some E3s, insights have emerged as to how their activity and
substrate interactions can be regulated. We now know that a wide va-
riety of protein–protein interactions are employed in substrate recog-
nition and that post-translational protein modiﬁcations are, in many
cases, critical to substrate binding. It is also evident that multiple sub-
strates can be targeted by one RING-type E3, and that multiple E3s
can target the same substrate. However, at both the cellular and or-
ganismal levels, the overall signiﬁcance of E3 redundancy in substrate
ubiquitination is, in general, poorly understood.
For substrates that are ubiquitinated on speciﬁc sites, with few ex-
ceptions, the factors that specify these sites are unknown. Progress
will require a marked expansion of our understanding of the position-
ing of both E2~Ub and the substrate in the context of the entire
RING-type ligase. Related to this, an emerging concept is that some
E2s function with RING-type ligases as ‘chain initiators,’ which put
the ﬁrst ubiquitin on a substrate, while others are ‘chain builders’
that add to an existing ubiquitin chain. Progress in parsing this issue
has been slowed by the fact that the most extensively studied E2s,
the UbcH5 (Ube2D) family, can perform both functions. In consider-
ing chain building, an important outstanding issue is whether differ-
ent E2s provide speciﬁc local environments around their active sites
favorable to particular lysines on acceptor ubiquitins, and thereby
favor certain ubiquitin chain linkages. If this is the case, understand-
ing the nature of these local environmental factors, and how they
are inﬂuenced by RING binding, will be crucial to appreciating how
the myriad of ubiquitin signals is generated.
Until recently, the molecular basis by which RING-type domains
stimulate the transfer of ubiquitin from E2 was enigmatic. As reviewed
herein, the pieces are falling into place for some E2:E3 pairs, as both
crystal and solution structures of RING-type domains complexed with
E2~Ub rather than E2 alone have recently been described and corrobo-
rated with functional data. These ﬁndings are all consistent with critical
roles for both a RING-induced closed E2~Ub conformation and the
RING's Zn II loop (or the equivalent in U-box proteins) in facilitating ac-
tivation. While these paradigm-shifting observations provide insights
into some aspects of the RING:E2 interface, they do not fully account
for defects in ubiquitination seen with mutations in other regions of
this interface. It will be necessary to expand upon the small number of
productive E3:E2 pairs that have been studied in depth to fully under-
stand this critical interface. Similarly, it is important to determine the
details and signiﬁcance of the RING:E2 binding interface for RING–
IBR–RING E3s, as we now know these function as classic catalysts,
akin to HECT-type E3s.
A common feature of RING-type domains is a tendency to form ac-
tive homo- and/or heterodimers. For C-terminal interleaved dimers,
the distal RING-type domain provides additional contacts to ubiquitin
(E2~Ub) to facilitate the closed E2~Ub conformation and promote
57M.B. Metzger et al. / Biochimica et Biophysica Acta 1843 (2014) 47–60catalysis. E3 dimerization/oligomerization, in instances where multi-
ple RING-type domains can bind E2~Ub, could also enhance the prob-
ability of successful ubiquitin chain formation by increasing the local
concentration of RING-type domains accessible to substrate. In the
cases of BRCA1–BARD1 and RING1B–Bmi1, which dimerize through
non-RING interactions, positioning of the second inactive (i.e.,
non-E2-binding) RING ﬁnger is not predicted to play a direct role in
the binding of E2 ~ Ub. In these cases, the function of dimerization
in ubiquitination remains enigmatic.
A central remaining question in RING-type E3-mediated
ubiquitination is what regulates the processivity of ubiquitination and
thus the fate of the substrate. The answer is likely complicated and in-
cludes E3 dimerization/oligomerization, the afﬁnity for substrate, the
relative afﬁnities for E2 versus E2~Ub, and ubiquitin-binding domains
intrinsic to E3s or E3 complexes. All of these potentially positive factors
are, of course, countered by DUBs that are associated with E3s or sub-
strates. Another factor that, in some cases, facilitates ubiquitination is
the non-covalent binding of ubiquitin to the backside of a subclass of
E2s. An emerging factor, reviewed herein, is the contribution of
non-RING regions of E3s binding to E2s using surfaces distinct from
the shared RING- and E1-interacting interface. In some cases, these in-
teractions compete with non-covalent ubiquitin backside binding and
limit ubiquitination. In other cases, binding to a similar region of the
E2 increases the afﬁnity of the E2:E3 interaction and thereby enhances
processivity of ubiquitination. These secondary sites of E2 binding may
also provide ameans to tether the E2 to the E3 complex,without contin-
uous RING ﬁnger binding, and thereby provide a potential means to
‘reload’ E2 with ubiquitin (E2~Ub) without dissociation from the E3
complex. Whether such E2-speciﬁc binding is of general importance
in vivo in determining combinatorial speciﬁcity in RING-type domain:
E2 interactions and in the processivity of ubiquitination now become
important questions.
Finally, RING-type E3s and their substrates are implicated in a wide
variety of human diseases ranging from viral infections to neurodegen-
erative disorders to cancer. Thus, they are attractive targets for thera-
peutic development. However, the lack of a catalytic center in
RING-type domains makes targeting strategies more difﬁcult. As bio-
chemical and biophysical/structural approaches converge on develop-
ing an understanding of speciﬁc aspects of RING-type E3s and their
interactions with E2s, the potential for generating therapeutics by in-
corporation of structure-based design becomes increasingly promising.
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